Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936465 · ClinicalTrials.gov registry record · Phase 1
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT03936465 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 41 participants.
The verdict
NCT03936465, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma. Arm 2 of this research study is studying an investigational drug called BMS-986378 (also known as CC-90010) as a possible treatment for pediatric brain tumors or pediatric tumors that have spread to the brain.
Interventions
- DRUG BMS-986158
- DRUG BMS-986378
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-09-27 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03936465
The ClinicalTrials.gov registry entry for NCT03936465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986158 is the first listed.
NCT03936465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03936465 about?
NCT03936465 is a clinical study titled "Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer". Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma. Arm 2 of this research study is studying an investigational drug called BMS-986378 (also known as CC-90010) as a possible treatment for pediatric brain t...
What is the current status of trial NCT03936465?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-09-27. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT03936465?
The interventions under investigation include: BMS-986158 (DRUG), BMS-986378 (DRUG).
Who is sponsoring clinical trial NCT03936465?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.